Anett Hellebø Ottesen

• Rugolo, Ilde; Shen, Xin; Støle, Thea Parsberg; Dahl, Anna Bergan; Manfra, Ornella & Lunde, Marianne [Show all 12 contributors for this article] (2025). Identification of a Small Secretoneurin Derivative That Inhibits CaMKIIδ Activity. Journal of Cellular and Molecular Medicine. ISSN 1582-1838. 29(20). doi: 10.1111/jcmm.70900. Full text in Research Archive Show summary

  ABSTRACT Ventricular arrhythmias, a major cause of sudden cardiac death, are driven by Ca 2+ imbalance in cardiac myocytes, often linked to the overactivation of CaMKIIδ (Ca 2+ /calmodulin‐dependent protein kinase II delta). As such, inhibiting CaMKIIδ represents a promising therapeutic strategy. Based on our previous finding that native secretoneurin (SN) is a weak CaMKIIδ inhibitor, we aimed to develop a more potent derivative of SN to effectively counter aberrant Ca 2+ handling and arrhythmia risk. Various regions of SN were tested for CaMKII binding, identifying the core region as the sequence with the strongest binding capacity. This region was subsequently optimised with two phenylalanine substitutions, resulting in the SN derivative SN‐db‐short. Structural homology modeling and ELISA‐based assays revealed that SN‐db‐short bound both the substrate‐binding (S‐site) region of CaMKIIδ, in addition to the ATP‐binding region, with 8‐fold stronger binding compared to SN. Surface plasmon resonance experiments confirmed that SN‐db‐short exhibited a higher association rate and affinity for CaMKIIδ compared to SN. Consistent with only a partial calmodulin binding motif, SN‐db‐short showed no calmodulin binding, indicating selective CaMKIIδ inhibition. In functional studies, SN‐db‐short inhibited CaMKIIδ‐mediated phosphorylation of ryanodine receptor 2 and appeared more effective than SN in reducing the incidence of Ca 2+ sparks and Ca 2+ waves. SN‐db‐short also more markedly inhibited CaMKIIδ phosphorylation of phospholamban, slowed Ca 2+ reuptake, and reduced the magnitude of Ca 2+ transients during isoproterenol stimulation. SN‐db‐short effectively inhibits CaMKIIδ and significantly counters aberrant Ca 2+ handling in cardiomyocytes. Thus, this optimised peptide holds therapeutic potential for reducing the risk of ventricular arrhythmias.

• Ottesen, Anett Hellebø; Røsjø, Helge Rørvik & Omland, Torbjørn (2025). Secretoneurin as a novel cardiovascular biomarker and potential therapeutic strategy. Expert Review of Cardiovascular Therapy. ISSN 1477-9072. 24(1), p. 21–27. doi: 10.1080/14779072.2025.2604574. Full text in Research Archive Show summary

  Introduction Secretoneurin (SN) is a prognostic biomarker in cardiovascular disease (CVD), and circulating SN concentrations have been associated with clinical outcomes in various cohort of CVDs. SN reflects other cellular pathways than established CV biomarkers, and SN provides incremental prognostic information to established CV risk indices. SN has been found to have several beneficial properties and SN could have potential as a future therapeutic strategy in CVD. Areas covered This review discusses SN as a novel cardiovascular biomarker and a potential therapeutic strategy in cardiovascular medicine. The authors have considered relevant papers identified by PubMed. Expert opinion SN is a prognostic biomarker in CVD, and unraveling the underlying pathophysiology of SN will be important to advance SN as a biomarker and potential future therapy in CVD. The future for SN as a biomarker and therapy is attractive and could be of future clinical relevance.

• Røsjø, Helge Rørvik; Rugolo, Ilde; Berg, Angelica Marianne; Faaren, Arne L; Frantzen, Frank & Christensen, Geir [Show all 11 contributors for this article] (2025). Secretoneurin Concentrations Measured with a High-Throughput Assay and Clinical Outcomes in Patients Hospitalized with Acute Dyspnea: Data from the Akershus Cardiac Examination 2 Study. The Journal of Applied Laboratory Medicine (JALM). ISSN 2576-9456. 10(3), p. 691–703. doi: 10.1093/jalm/jfaf011. Full text in Research Archive Show summary

  Background High-throughput assays are required for novel biomarkers to have clinical potential. Secretoneurin (SN) is a candidate biomarker, and the performance of a new high-throughput SN assay is not known. Methods We measured SN concentrations with a prototype chemiluminescent immunoassay (CLIA) in 299 patients hospitalized with acute dyspnea. We compared the results with a CE-marked SN enzyme linked immunosorbent assay (ELISA). We adjudicated the cause of dyspnea as heart failure (HF) or non-HF, and we obtained information on all-cause mortality during follow-up. Results SN concentrations measured with CLIA and ELISA were closely correlated: rho = 0.81, P < 0.001. SN CLIA concentrations were higher in HF patients (n = 129) compared to patients with non-HF-related dyspnea (n = 170): median 51 (quartile 1–3 40–69) vs 41 (32–54) pmol/L, P < 0.001. The area under the curve (AUC) of SN CLIA to diagnose HF was 0.64 (95% CI, 0.58–0.71) and the AUC of N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 0.85 (0.81–0.89). During median 818 days follow-up, 110 patients died (37%). There was a nonlinear association between SN CLIA concentrations and mortality with optimal cutpoint 53 pmol/L. SN CLIA concentrations >53 pmol/L were associated with mortality after adjusting for clinical variables and NT-proBNP and cardiac troponin T concentrations: hazard ratio 1.7 (95% CI, 1.1–2.7), AUC 0.67 (0.61–0.74). We found similar results for SN ELISA for diagnosis and prognosis with AUC 0.63 (0.57–0.70) for the prediction of mortality. Conclusion The high-throughput SN CLIA correlates with the SN ELISA and provides independent prognostic information over established biomarkers in patients with acute dyspnea.

• Røsjø, Helge Rørvik; Meessen, Jennifer; Ottesen, Anett Hellebø; Latini, Roberto & Omland, Torbjørn (2023). Prognostic value of secretoneurin in chronic heart failure. Data from the GISSI-Heart Failure trial. Clinical Biochemistry. ISSN 0009-9120. 118. doi: 10.1016/j.clinbiochem.2023.110595. Full text in Research Archive Show summary

  Background Circulating secretoneurin (SN) concentrations have been found to provide prognostic information in patients with acute heart failure. We wanted to assess whether SN would improve prognostication also in patients with chronic heart failure (HF) in a large multicenter trial. Methods We measured plasma SN concentrations at randomization (n = 1224) and after 3 months (n = 1103) in patients with chronic, stable HF from the GISSI-HF study. The co-primary endpoints were (1) time to death or (2) admission to hospital for cardiovascular reasons. Results Mean age was 67 years and 80% were male. Median (quartile 1–3) SN concentrations were 42.6 (35.0–62.8) pmol/L on randomization and 42.0 (34.5–53.1) pmol/L after 3 months, which are higher than SN concentrations in healthy subjects. Higher SN concentrations at randomization were associated with lower body-mass index (BMI), lower systolic blood pressure, lower estimated glomerular filtration rate (eGFR), higher B-type natriuretic peptide (BNP) concentrations, and diagnosis of chronic obstructive pulmonary disease. During median follow-up of 3.9 years, 344 patients (27.0%) died. After adjusting for age, sex, left ventricular ejection fraction, BMI, functional class, ischemic etiology, heart rate, blood pressure, eGFR, bilirubin, comorbidities, and BNP concentrations, logarithmically transformed SN concentrations on randomization were associated with mortality (HR 2.60 (95% CI 1.01–6.70), p = 0.047). SN concentrations were also associated with admission to hospital for cardiovascular reasons, but the association was attenuated and no longer significant in multivariable analysis. Conclusion Plasma SN concentrations provided incremental prognostic information to established risk indices and biomarkers in a large cohort of chronic HF patients.

• Aakre, Kristin Moberg; Ottesen, Anett Hellebø; Strand, Heidi; Faaren, Arne L.; Alaour, Bashir & Torsvik, Janniche [Show all 11 contributors for this article] (2021). Biological variation of secretoneurin; a novel cardiovascular biomarker implicated in arrhythmogenesis. Clinical Biochemistry. ISSN 0009-9120. 98, p. 74–77. doi: 10.1016/j.clinbiochem.2021.09.014. Full text in Research Archive Show summary

  Background Secretoneurin is a novel prognostic biomarker that may predict mortality in heart failure and the occurrence of ventricular arrhythmias. This study reports the within subject variation (CVI), between subject variation (CVG), reference change values (RCV) and index of individuality (II) of secretoneurin. Methods Thirty healthy volunteers were included. Non-fasting samples were obtained between 8 and 10 am once a week for ten weeks. Secretoneurin was analyzed in duplicate using ELISA. No outliers were present according to Burnett and Reeds‘ criteria. Simple linear regression did not identify significant trends. Variance homogeneity in the analytical variance and CVI were tested using Cochrane’s and Bartlett’s tests and four participants were excluded. Calculation of CVI, CVG and RCV were done on ln transformed data as described by Fokkema, the II was calculated using retransformed data. Results The median age of the participants was 36 years and 53% were female. Non-fasting glucose, eGFR(CKD-EPI), cTnT and NT-proBNP concentrations were within the normal range. Median secretoneurin concentrations were 38 pmol/L (women) and 33 pmol/L (men), p-value < 0.001. CVI and CVG were 9.8% (CI 8.7% to 11.0%) and 20.0 (CI 15.4% to 28.0%), respectively. RCV were 38.7% (CI 35.5% to 42.7%) and −27.9 (CI −29.9 to −26.2) and the II were 0.60 (CI 0.42–0.78). No gender differences were present. Conclusion Secretoneurin has a fairly low CVI, CVG, RCV and II, indicating that it could be suitable as a diagnostic or prognostic biomarker and that delta values in serial samplings may be preferable for identifying clinical changes.

• Myhre, Peder Langeland; Ottesen, Anett Hellebø; Faaren, Arne L.; Tveit, Sjur Hansen; Springett, Jon & Pyylampi, Johanna [Show all 11 contributors for this article] (2021). Performance of a Novel Research-Use-Only Secretoneurin ELISA in Patients with Suspected Acute Coronary Syndrome: Comparison with an Established Secretoneurin Radioimmunoassay. Cardiology. ISSN 0008-6312. 146(5), p. 566–574. doi: 10.1159/000517444. Full text in Research Archive Show summary

  Background: Circulating secretoneurin (SN) concentrations, as measured by established radioimmunoassay (RIA), risk stratify patients with cardiovascular disease. We now report data for a recently developed research-use-only SN enzyme-linked immunosorbent assay (ELISA) in patients with suspected acute coronary syndrome (ACS). Methods: SN ELISA was developed according to industry standards and tested in 401 unselected chest pain patients. Blood samples were drawn <24 h from admission, and we adjudicated all hospitalizations as ACS or non-ACS. The mean follow-up was 6.2 years. Results: SN ELISA with 2 monoclonal sheep anti-SN antibodies has a measuring range of 10–250 pmol/L and demonstrates excellent analytical precision and accuracy across the range of SN concentrations. SN measured by ELISA and RIA correlated in the chest pain patients: rho = 0.39, p < 0.001. SN concentrations were higher in ACS patients (n = 161 [40%]) than in non-ACS patients (n = 240) for both assays, with an area under the curve (AUC) of 0.66 (95% CI: 0.61–0.71) for ELISA and 0.59 (0.54–0.65) for RIA. SN concentrations were also higher in nonsurvivors (n = 65 [16%]) than survivors, with an AUC of 0.72 (0.65–0.79) for ELISA versus 0.64 (0.56–0.72) for RIA, p = 0.007, for difference between assays. Adjusting for age, sex, blood pressure, previous myocardial infarction, atrial fibrillation, and heart failure in multivariable analysis, SN concentrations as measured by ELISA, but not RIA, remained associated with mortality, with a hazard ratio of 1.71 (1.03–2.84), p = 0.038. Conclusions: The novel SN ELISA has excellent performance, higher AUC for diagnosis, and superior prognostic accuracy compared to the established RIA in chest pain patients.

• Brynildsen, Jon; Petaja, Liisa; Myhre, Peder Langeland; Lyngbakken, Magnus; Nygård, Ståle & Stridsberg, Mats [Show all 11 contributors for this article] (2019). Circulating Secretoneurin Concentrations After Cardiac Surgery: Data From the FINNish Acute Kidney Injury Heart Study. Critical Care Medicine. ISSN 0090-3493. 47(5), p. e412–e419. doi: 10.1097/CCM.0000000000003670. Full text in Research Archive
• Ottesen, Anett Hellebø; Carlson, Cathrine Rein; Eken, Olav Søvik; Sadredini, Mani; Myhre, Peder Langeland & Shen, Xin [Show all 24 contributors for this article] (2019). Secretoneurin Is an Endogenous Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor That Attenuates Ca2+-Dependent Arrhythmia. Circulation: Arrhythmia and Electrophysiology. ISSN 1941-3149. 12(4). doi: 10.1161/CIRCEP.118.007045. Full text in Research Archive Show summary

  Background: Circulating SN (secretoneurin) concentrations are increased in patients with myocardial dysfunction and predict poor outcome. Because SN inhibits CaMKIIδ (Ca2+/calmodulin-dependent protein kinase IIδ) activity, we hypothesized that upregulation of SN in patients protects against cardiomyocyte mechanisms of arrhythmia. Methods: Circulating levels of SN and other biomarkers were assessed in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT; n=8) and in resuscitated patients after ventricular arrhythmia–induced cardiac arrest (n=155). In vivo effects of SN were investigated in CPVT mice (RyR2 [ryanodine receptor 2]-R2474S) using adeno-associated virus-9–induced overexpression. Interactions between SN and CaMKIIδ were mapped using pull-down experiments, mutagenesis, ELISA, and structural homology modeling. Ex vivo actions were tested in Langendorff hearts and effects on Ca2+ homeostasis examined by fluorescence (fluo-4) and patch-clamp recordings in isolated cardiomyocytes. Results: SN levels were elevated in patients with CPVT and following ventricular arrhythmia–induced cardiac arrest. In contrast to NT-proBNP (N-terminal pro-B-type natriuretic peptide) and hs-TnT (high-sensitivity troponin T), circulating SN levels declined after resuscitation, as the risk of a new arrhythmia waned. Myocardial pro-SN expression was also increased in CPVT mice, and further adeno-associated virus-9–induced overexpression of SN attenuated arrhythmic induction during stress testing with isoproterenol. Mechanistic studies mapped SN binding to the substrate binding site in the catalytic region of CaMKIIδ. Accordingly, SN attenuated isoproterenol induced autophosphorylation of Thr287-CaMKIIδ in Langendorff hearts and inhibited CaMKIIδ-dependent RyR phosphorylation. In line with CaMKIIδ and RyR inhibition, SN treatment decreased Ca2+ spark frequency and dimensions in cardiomyocytes during isoproterenol challenge, and reduced the incidence of Ca2+ waves, delayed afterdepolarizations, and spontaneous action potentials. SN treatment also lowered the incidence of early afterdepolarizations during isoproterenol; an effect paralleled by reduced magnitude of L-type Ca2+ current. Conclusions: SN production is upregulated in conditions with cardiomyocyte Ca2+ dysregulation and offers compensatory protection against cardiomyocyte mechanisms of arrhythmia, which may underlie its putative use as a biomarker in at-risk patients.

• Ottesen, Anett Hellebø; Carlson, Cathrine Rein; Louch, William Edward; Dahl, Mai Britt; Sandbu, Ragnhild Askeland & Johansen, Rune Forstrøm [Show all 15 contributors for this article] (2017). Glycosylated Chromogranin A in Heart Failure: Implications for Processing and Cardiomyocyte Calcium Homeostasis. Circulation: Heart Failure. ISSN 1941-3289. 10(2). doi: 10.1161/CIRCHEARTFAILURE.116.003675. Full text in Research Archive Show summary

  Background—Chromogranin A (CgA) levels have previously been found to predict mortality in heart failure (HF), but currently no information is available regarding CgA processing in HF and whether the CgA fragment catestatin (CST) may directly influence cardiomyocyte function. Methods and Results—CgA processing was characterized in postinfarction HF mice and in patients with acute HF, and the functional role of CST was explored in experimental models. Myocardial biopsies from HF, but not sham-operated mice, demonstrated high molecular weight CgA bands. Deglycosylation treatment attenuated high molecular weight bands, induced a mobility shift, and increased shorter CgA fragments. Adjusting for established risk indices and biomarkers, circulating CgA levels were found to be associated with mortality in patients with acute HF, but not in patients with acute exacerbation of chronic obstructive pulmonary disease. Low CgA-to-CST conversion was also associated with increased mortality in acute HF, thus, supporting functional relevance of impaired CgA processing in cardiovascular disease. CST was identified as a direct inhibitor of CaMKIIδ (Ca2+/calmodulin-dependent protein kinase IIδ) activity, and CST reduced CaMKIIδ-dependent phosphorylation of phospholamban and the ryanodine receptor 2. In line with CaMKIIδ inhibition, CST reduced Ca2+ spark and wave frequency, reduced Ca2+ spark dimensions, increased sarcoplasmic reticulum Ca2+ content, and augmented the magnitude and kinetics of cardiomyocyte Ca2+ transients and contractions. Conclusions—CgA-to-CST conversion in HF is impaired because of hyperglycosylation, which is associated with clinical outcomes in acute HF. The mechanism for increased mortality may be dysregulated cardiomyocyte Ca2+ handling because of reduced CaMKIIδ inhibition.

• Ottesen, Anett Hellebø; Christensen, Geir Arve; Omland, Torbjørn & Røsjø, Helge (2017). Glycosylated Chromogranin A: Potential Role in the Pathogenesis of Heart Failure. Current Heart Failure Reports. ISSN 1546-9530. 14, p. 478–478. doi: 10.1007/s11897-017-0360-x. Full text in Research Archive Show summary

  Purpose of Review Endocrine and paracrine factors influence the cardiovascular system and the heart by a number of different mechanisms. The chromogranin-secretogranin (granin) proteins seem to represent a new family of proteins that exerts both direct and indirect effects on cardiac and vascular functions. The granin proteins are produced in multiple tissues, including cardiac cells, and circulating granin protein concentrations provide incremental prognostic information to established risk indices in patients with myocardial dysfunction. In this review, we provide recent data for the granin proteins in relation with cardiovascular disease, and with a special focus on chromogranin A and heart failure. Recent Findings Chromogranin A is the most studied member of the granin protein family, and shorter, functionally active peptide fragments of chromogranin A exert protective effects on myocardial cell death, ischemia-reperfusion injury, and cardiomyocyte Ca2+ handling. Granin peptides have also been found to induce angiogenesis and vasculogenesis. Protein glycosylation is an important post-translational regulatory mechanism, and we recently found chromogranin A molecules to be hyperglycosylated in the failing myocardium. Chromogranin A hyperglycosylation impaired processing of full-length chromogranin A molecules into physiologically active chromogranin A peptides, and patients with acute heart failure and low rate of chromogranin A processing had increased mortality compared to other acute heart failure patients. Other studies have also demonstrated that circulating granin protein concentrations increase in parallel with heart failure disease stage. Summary The granin protein family seems to influence heart failure pathophysiology, and chromogranin A hyperglycosylation could directly be implicated in heart failure disease progression. This is a post-peer-review, pre-copyedit version of an article published in Current Heart Failure Reports. The final authenticated version is available online at: http://dx.doi.org/10.1007/s11897-017-0360-x

• Myhre, Peder Langeland; Ottesen, Anett Hellebø; Okkonen, Marjatta; Linko, Rita; Stridsberg, Mats & Nygård, Ståle [Show all 10 contributors for this article] (2016). Prognostic value of secretoneurin in patients with acute respiratory failure:Data from the FINNALI study. Clinical Chemistry. ISSN 0009-9147. 62(10), p. 1380–1389. doi: 10.1373/clinchem.2016.258764. Full text in Research Archive
• Røsjø, Helge; Stridsberg, Mats; Ottesen, Anett Hellebø; Nygård, Ståle; Christensen, Geir Arve & Pettilä, Ville [Show all 11 contributors for this article] (2016). Prognostic Value of Secretoneurin in Critically Ill Patients with Infections. Critical Care Medicine. ISSN 0090-3493. 44(10), p. 1882–1890. doi: 10.1097/CCM.0000000000001832. Full text in Research Archive
• Ottesen, Anett Hellebø; Louch, William Edward; Carlson, Cathrine Rein; Landsverk, Ole J. B.; Kurola, Jouni & Johansen, Rune Forstrøm [Show all 18 contributors for this article] (2015). Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling. Journal of the American College of Cardiology. ISSN 0735-1097. 65(4), p. 339–351. doi: 10.1016/j.jacc.2014.10.065. Full text in Research Archive
• Landsverk, Ole J. B.; Ottesen, Anett Hellebø; Berg-Larsen, Axel; Appel, Silke & Bakke, Oddmund (2012). Differential regulation of MHC II and invariant chain expression during maturation of monocyte-derived dendritic cells. Journal of Leukocyte Biology. ISSN 0741-5400. 91(5), p. 729–737. doi: 10.1189/jlb.0311150. Full text in Research Archive
• Røsjø, Helge; Stridsberg, Mats; Florholmen, Geir; Stensløkken, Kåre-Olav; Ottesen, Anett Hellebø & Sjaastad, Ivar [Show all 12 contributors for this article] (2012). Secretogranin II; a Protein Increased in the Myocardium and Circulation in Heart Failure with Cardioprotective Properties. PLOS ONE. 7(5). doi: 10.1371/journal.pone.0037401. Full text in Research Archive

View all works in NVA

• Ottesen, Anett Hellebø; Carlson, Cathrine Rein; Laver, Derek R; Myhre, Peder Langeland; Dalhus, Bjørn & Lunde, Per Kristian [Show all 14 contributors for this article] (2017). Secretoneurin is an Endogenous CaMKII Inhibitor That Attenuates Ca2+-Dependent Arrhythmogenesis. Circulation. ISSN 0009-7322. 136, p. A13900–A13900. Full text in Research Archive
• Ottesen, Anett; Carlson, Cathrine; Edwards, Andrew; Landsverk, Ole; Johansen, Rune & Moe, Morten [Show all 10 contributors for this article] (2015). Secretoneurin, a Novel Endogenous CaMKII Inhibitor, Augments Cardiomyocyte Calcium Handling and Inhibits Arrhythmogenic Calcium Release. Full text in Research Archive
• Sandbu, Ragnhild Askeland; Dahl, Mai Britt; Ottesen, Anett Hellebø; Jørgensen, M; Stridsberg, Mats & Sjaastad, Ivar [Show all 10 contributors for this article] (2015). Chromogranin A is glycosylated in acute heart failure and this is associated with reduced processing to the functional peptide catestatin and increased mortality. Full text in Research Archive
• Ottesen, Anett Hellebø; Carlson, Cathrine Rein; Louch, William Edward; Johansen, Rune F.; Stridsberg, Mats & Jarstadmarken, Hilde [Show all 12 contributors for this article] (2015). Chromogranin A is a potent prognostic biomarker in acute heart failure, and its fragment catestatin regulates cardiomyocyte calcium homeostasis by CaMKII inhibition. Full text in Research Archive
• Ottesen, Anett Hellebø; Carlson, Cathrine Rein; Louch, William Edward; Dahl, Mai Britt; Sandbu, Ragnhild Askeland & Johansen, Rune F. [Show all 15 contributors for this article] (2015). Enhanced myocardial chromogranin A glycosylation in acute heart failure: reduced processing and potential impact on cardiomyocyte calcium homeostasis. Full text in Research Archive
• Ottesen, Anett Hellebø; Carlson, Cathrine Rein; Edwards, Andrew; Landsverk, Ole J. B.; Johansen, Rune Forstrøm & Moe, Morten Kaare [Show all 12 contributors for this article] (2015). Secretoneurin,a novel endogenous CaMKII inhibitor, augments cardiomyocyte Calcium handling and inhibits arrhythmogenic Calcium release. Biophysical Journal. ISSN 0006-3495. 108, p. 340a–340a. Full text in Research Archive
• Ottesen, Anett Hellebø; Laver, Derek; Christensen, Geir Arve; Røsjø, Helge & Louch, William Edward (2015). Secretoneurin a novel endogenous CaMKIIð inhibitor, inhibits Ca2+ dependent arrhythmogenesis. Full text in Research Archive
• Ottesen, Anett Hellebø; Louch, William Edward; Carlson, Cathrine Rein; Landsverk, Ole J. B.; Kurola, Jouni & Johansen, Rune Forstrøm [Show all 18 contributors for this article] (2014). Secretoneurin provides independent prognostic information in patients with heart failure and cardiac arrest, and has a direct inhibitory effect on diastolic Ca2+ leak and arrhythmogenic Ca2+ waves via CaMKII inhibition. Circulation Research. ISSN 0009-7330. 115. Full text in Research Archive
• Ottesen, Anett Hellebø; Carlson, Cathrine Rein; Louch, William Edward; Stridsberg, Mats; Høiseth, Arne Didrik & Brynildsen, Jon [Show all 10 contributors for this article] (2014). Chromogranin A is a potent risk marker in acute heart failure and directly associated with cardiomyocyTe Ca2+ handling. European Heart Journal. ISSN 0195-668X. 35, p. 328–328. Full text in Research Archive
• Ottesen, Anett Hellebø; Carlson, Cathrine Rein; Louch, William Edward; Høiseth, Arne Didrick; Brynildsen, Jon & Stridsberg, Mats [Show all 9 contributors for this article] (2014). Chromogranin A directly modifies cardiomyocyte Ca2+ homeostasis via CaMKII inhibition and is a strong prognostic biomarker in acute heart failure. Full text in Research Archive
• Ottesen, Anett Hellebø; Louch, William Edward; Carlson, Cathrine Rein; Landsverk, Ole J. B.; Johansen, Rune Forstrøm & Moe, Morten Kaare [Show all 10 contributors for this article] (2013). Secretoneurin regulates cardiomyocyte calcium homeostasis via CaMKII inhibition and is a potent marker of mortality in patients with acute heart failure. European Heart Journal. ISSN 0195-668X. 34, p. 6–7. Full text in Research Archive
• Ottesen, Anett Hellebø; Louch, William Edward; Carlson, Cathrine Rein; Landsverk, Ole J. B.; Johansen, Rune forstrom & Moe, Morten Carsten [Show all 14 contributors for this article] (2013). Secretoneurin regulates cardiomyocyte calcium homeostasis via CaMKIIinhibition and is a potent marker of mortality in patients with acute heart failure. Full text in Research Archive
• Ottesen, Anett Hellebø; Louch, William Edward; Carlson, Cathrine Rein; Landsverk, Ole J. B.; Johansen, Rune forstrom & Moe, Morten [Show all 14 contributors for this article] (2013). Secretoneurin is a novel endogenous CaMKII inhibitor that regulates cardiomyocyte calcium handling and is closely associated with mortality in patients with acute heart failure. Circulation. ISSN 0009-7322. 128. Full text in Research Archive
• Ottesen, Anett Hellebø; Louch, William Edward; Carlson, Cathrine Rein; Landsverk, Ole J. B.; Johansen, Rune forstrom & Moe, Morten [Show all 10 contributors for this article] (2013). Secretoneurin regulates cardiomyocyte calcium homeostasis CaMKIIinhibition and is a potent marker of mortality in patients with acute heart failure. Full text in Research Archive
• Ottesen, Anett Hellebø; Louch, William Edward; Carlson, Cathrine Rein; Landsverk, Ole J. B.; Johansen, Rune Forstrom & Moe, Morten [Show all 14 contributors for this article] (2013). 32. Secretoneurin is a novel endogenous CaMKII inhibitor that regulates cardiomyocyte calcium handling and is closely associated with mortality in patients with acute heart failure. Full text in Research Archive
• Ottesen, Anett Hellebø; Louch, William Edward; Carlson, C.; Landsverk, Ole J. B.; Stridsberg, M. & Omland, Torbjørn [Show all 8 contributors for this article] (2012). Secretoneurin, a peptide from the chromogranin-secretogranin family, regulates cardiomyocyte calcium homeostasis. European Heart Journal. ISSN 0195-668X. 33, p. 1044–1044. Full text in Research Archive
• Ottesen, Anett Hellebø; Louch, William Edward; Carlson, Cathrine Rein; Landsverk, Ole J. B.; Stridsberg, Mats & Sjaastad, Ivar [Show all 10 contributors for this article] (2012). Secretoneurin is increased in the myocardium in heart failure and may influence pathophysiology by modulating cardiomyocyte calcium homeostasis. Full text in Research Archive
• Ottesen, Anett Hellebø; Louch, William Edward; Carlson, Cathrine Rein; Landsverk, Ole J. B.; Stridsberg, Mats & Omland, Torbjørn [Show all 8 contributors for this article] (2012). Secretoneurin is an inhibitor of CaMKII activity in heart. Full text in Research Archive
• Ottesen, Anett Hellebø; Louch, William Edward; Carlson, Cathrine Rein; Landsverk, Ole J. B.; Høiseth, Arne Didrik & Stridsberg, Mats [Show all 9 contributors for this article] (2012). Secretoneurin regulates cardiomyocyte calcium homeostasis and is a potent marker of mortality in patients with heart failure. Full text in Research Archive
• Ottesen, Anett Hellebø; Louch, William Edward; Carlson, Cathrine Rein; Landsverk, Ole J. B.; Stridsberg, Mats & Sjaastad, Ivar [Show all 10 contributors for this article] (2012). Secretoneurin is increased in the myocardium in heart failure and may influence pathophysiology by modulating cardiomyocyte calcium homeostasis. Cardiovascular Research (CVR). ISSN 0008-6363. 93, p. S108–S109. doi: 10.1093/cvr/cvr336. Full text in Research Archive
• Ottesen, Anett Hellebø; Louch, William Edward; Carlson, Cathrine Rein; Landsverk, Ole J. B.; Høiseth, Arne Didrik & Stridsberg, Mats [Show all 10 contributors for this article] (2011). Secretoneurin, a peptide associated with mortality in heart failure, modulates cardiomyocyte calcium homeostasis. Full text in Research Archive
• Ottesen, Anett Hellebø; Louch, William Edward; Carlson, Cathrine Rein; Landsverk, Ole J. B.; Høiseth, Arne Didrik & Stridsberg, Mats [Show all 10 contributors for this article] (2011). Secretoneurin, a peptide associated with mortality in heart failure, modulates cardiomyocyte calcium homeostasis. Full text in Research Archive
• Ottesen, Anett Hellebø; Louch, William Edward; Carlson, Cathrine Rein; Landsverk, Ole J. B.; Høiseth, Arne Didrik & Stridsberg, Mats [Show all 10 contributors for this article] (2011). Secretoneurin, a peptide associated with mortality in heart failure, modulates cardiomyocyte calcium homeostasis. Circulation. ISSN 0009-7322. 124. Full text in Research Archive
• Ottesen, Anett Hellebø (2017). Functional aspects of granin proteins in cardiac disease. Universitetet i Oslo. ISSN 9788283333916. Full text in Research Archive
• Ottesen, Anett Hellebø & Røsjø, Helge (2017). Functional aspects of granin proteins in Cardiac disease. Universitetet i Oslo. ISSN 9788283333916. Full text in Research Archive

View all works in NVA